2018
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer.
Socinski M, Von Pawel J, Kasahara K, Bondarenko I, Syrigos K, Vladimirov V, Bryl M, Zereu M, Bair A, Hilton F, Liau K, Herbst R. A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. Journal Of Clinical Oncology 2018, 36: 109-109. DOI: 10.1200/jco.2018.36.15_suppl.109.Peer-Reviewed Original Research
2016
Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
Semrad T, Redman M, Herbst R, Kim E, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold S, Varella-Garcia M, Moon J, Mack P, Blanke C, Hirsch F, Kelly K, Gandara D. Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2016, 34: 9082-9082. DOI: 10.1200/jco.2016.34.15_suppl.9082.Peer-Reviewed Original Research
2009
VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2009, 69: 337-340. PMID: 20036440, PMCID: PMC2891357, DOI: 10.1016/j.lungcan.2009.11.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungDisease ProgressionDisease-Free SurvivalErlotinib HydrochlorideFemaleHumansLung NeoplasmsMaleMass SpectrometryMiddle AgedNeoplasm Recurrence, LocalPrecision MedicinePredictive Value of TestsProteomeQuinazolinesConceptsNon-small cell lung cancer patientsCell lung cancer patientsAdvanced NSCLC patientsCombination of erlotinibLung cancer patientsToxic regimenNSCLC patientsPretreatment serumCancer patientsWorse outcomesProteomic classifierBlinded mannerPatientsErlotinibBevacizumabVeriStratSurvivalTreatmentRegimenProgressionSerum
2008
Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone
Dang T, Salmon J, Chen H, Chen S, Lee J, Sandler A, Herbst R, Brahmer J, Carbone D, Shyr Y. Predictive value of serum MALDI-TOF proteomic profiling from patients treated with erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone. Journal Of Clinical Oncology 2008, 26: 11014-11014. DOI: 10.1200/jco.2008.26.15_suppl.11014.Peer-Reviewed Original ResearchVeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab
Salmon J, Dang T, Billheimer D, Roder H, Grigorieva J, Tsypin M, Herbst R, Tsao A, Tran H, Carbone D. VeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab. Journal Of Clinical Oncology 2008, 26: 8008-8008. DOI: 10.1200/jco.2008.26.15_suppl.8008.Peer-Reviewed Original Research
2005
Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene
Tsao A, Herbst R, Sandler A, Seshagiri S, Wistuba I, Henderson T, Ramies D, Goddard A, Johnson D, Eberhard D. Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene. Journal Of Clinical Oncology 2005, 23: 7092-7092. DOI: 10.1200/jco.2005.23.16_suppl.7092.Peer-Reviewed Original Research
2004
Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer
Sandler A, Blumenschein G, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson D, Herbst R. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Journal Of Clinical Oncology 2004, 22: 2000-2000. DOI: 10.1200/jco.2004.22.14_suppl.2000.Peer-Reviewed Original ResearchPhase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer
Sandler A, Blumenschein G, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson D, Herbst R. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Journal Of Clinical Oncology 2004, 22: 2000-2000. DOI: 10.1200/jco.2004.22.90140.2000.Peer-Reviewed Original Research
2003
977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer
Herbst R, Mininberg E, Henderson T, Kim E, Hong W, Mass R, Novotny W, Garcia B, Johnson D, Sandler A. 977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer. European Journal Of Cancer Supplements 2003, 1: s293. DOI: 10.1016/s1359-6349(03)91004-4.Peer-Reviewed Original ResearchO-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer
Sandler A, Mininberg E, Henderson T, Kim E, Hong W, Mass R, Novotny W, Garcia B, Herbst R, Johnson D. O-112 A phase I/II study of the anti-VEGF MAb bevacizumab (Avastin™) and erlotinib (Tarceva™), a HER1/EGFR-TK inhibitor: a multi-faceted approach for the treatment of recurrent non-small cell lung cancer. Lung Cancer 2003, 41: s36. DOI: 10.1016/s0169-5002(03)91770-3.Peer-Reviewed Original Research